-Lead and support all aspects of company building and operations including: deal sourcing, technical and business diligence, talent recruitment, contract negotiations, project management, budget oversight, corporate and business development, preparing and presenting board meeting materials

-Lead and support all aspects of company building including: deal sourcing, diligence, company operations-Company creation activities: Petra Pharma ($48M); Lodo Therapeutics ($17M); ApoGen, deal lead ($7M)-Source new deals by attending networking events, startup pitch competitions and conferences, relationship building with tech transfer officers and key faculty, scientific literature review-Perform diligence activities including: competitive landscape and market analyses, engaging KOLs, collaborating with pharma partners on diligence, building research plans and associated budgets and drafting investment memos-Support company operations including: sourcing key personnel, identifying and facilitating business development opportunities, project and CRO management, scientific oversight and preparing board meeting decks-Manage deal flow by logging and tracking all opportunities in a database, running weekly triage meetings, tracking action item progress by team; provide deal flow analytics to CEO for presentation to investors-Generate monthly dashboard updates of portfolio companies for CEO to share with board of directors

-Research scientific literature and current trends in oncology drug discovery and development to identify and propose novel drug targets to senior management-Collaborate with cross-functional team members, locally and globally, to develop experimental research plans and coordinate research activities in support of new target ideas-Summarize research and present findings at internal project team meetings to the senior management -Leading biology efforts for early-stage new target projects through validation towards go/no-go decision points-created "New Targets Working Group", aimed to bring together scientists working on new target projects in order to share ongoing project data, best practices and troubleshoot technical issues-Member of "Early Portfolio Group" tasked to propose, evaluate and prioritize new targets-Performing and managing triage, due diligence and legal activities associated with early-stage (preclinical through Phase I) business development opportunities, coordinating communications with external parties and attending face to face meetings with potential partners-Attend and contribute to roundtable discussions with invited academic speakers to discuss potential areas of collaboration-Scouting for new targets and technologies at scientific conferences

Investigating the role of autophagy in the pathogenesis and treatment of cancer. I am developing cell-based drug discovery tools for target validation and mechanism of action studies of a cancer metabolism target of interest within the autophagy pathway. I am additionally exploring potential biomarkers for predicting whether specific tumor subtypes are sensitive or resistant to autophagy inhibition.

Investigating the molecular and genetic pathogenesis of diffuse large B-cell lymphoma. Using a combination of genome-wide approaches, in vitro functional assays and in vivo mouse models, we are elucidating the role of recurrently mutated genes in the pathogenesis of DLBCL.

Investigating the molecular and genetic pathogenesis of diffuse large B-cell lymphoma. Using a combination of genome-wide approaches, in vitro functional assays and in vivo mouse models, we are elucidating the role of recurrently mutated genes in the pathogenesis of DLBCL.